Published in Circulation on April 05, 2011
Universal definition of myocardial infarction. Circulation (2007) 11.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Reversal of ischemia of donor artery myocardium after recanalization of a chronic total occlusion. Catheter Cardiovasc Interv (2013) 2.71
2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol (2014) 2.58
Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol (2002) 2.47
Pseudoaneurysm of the mitral-aortic intervalvular fibrosa (MAIVF): A comprehensive review. J Am Soc Echocardiogr (2010) 2.24
The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention. J Am Coll Cardiol (2012) 2.13
Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation (2006) 2.00
Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res (2005) 1.78
Late coronary stent thrombosis: early vs. late stent thrombosis in the stent era. Catheter Cardiovasc Interv (2002) 1.62
Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther (2006) 1.58
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther (2007) 1.56
Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation (2003) 1.55
The effect of CTO recanalization on FFR of the donor artery. Catheter Cardiovasc Interv (2011) 1.54
The current status and future direction of percutaneous coronary intervention without on-site surgical backup: an expert consensus document from the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv (2007) 1.53
Treatment of the chronic total occlusion: a call to action for the interventional community. Catheter Cardiovasc Interv (2014) 1.46
The myocardium supplied by a chronic total occlusion is a persistently ischemic zone. Catheter Cardiovasc Interv (2013) 1.45
Quality assessment and improvement in interventional cardiology: a Position Statement of the Society of Cardiovascular Angiography and Interventions, Part II: public reporting and risk adjustment. Catheter Cardiovasc Interv (2011) 1.42
Prolonged high-pressure is required for optimal stent deployment as assessed by optical coherence tomography. Catheter Cardiovasc Interv (2013) 1.42
Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis. Am J Cardiol (2007) 1.42
Cardiac arrest on induction of anesthesia due to triple vessel coronary artery disease despite a "Negative" angiogram. Anesthesiology (2002) 1.40
Symptomatic right ventricular ischemia secondary to a critical stenosis in a nondominant right coronary artery. Catheter Cardiovasc Interv (2012) 1.40
Treatment of chronic total occlusion by retrograde passage of stents through an epicardial collateral vessel. Catheter Cardiovasc Interv (2008) 1.40
Grade 3 ischemia on admission electrocardiogram and chest pain duration predict failure of ST-segment resolution after primary percutaneous coronary intervention for acute myocardial infarction. J Electrocardiol (2006) 1.39
Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual? Catheter Cardiovasc Interv (2008) 1.39
Retrograde fractional flow reserve and recanalization of a chronic total occlusion of a saphenous venous graft. Catheter Cardiovasc Interv (2012) 1.39
Left atrial inflow and outflow obstruction as a complication of retrograde approach for chronic total occlusion: report of a case and literature review of left atrial hematoma after percutaneous coronary intervention. Catheter Cardiovasc Interv (2013) 1.38
Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol (2005) 1.23
Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv (2007) 1.14
Left main coronary artery thrombus: a case series with different outcomes. J Thromb Thrombolysis (2005) 1.06
Ventricular free wall rupture following acute myocardial infarction. Coron Artery Dis (2003) 1.05
The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol (2008) 1.03
The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol (2004) 1.02
The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. Am J Physiol Heart Circ Physiol (2007) 1.00
A novel minimal-invasive model of chronic myocardial infarction in swine. Coron Artery Dis (2004) 1.00
Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostaglandins Other Lipid Mediat (2006) 0.99
Determining the significance of side branch lesion during bifurcation stenting. Am J Cardiol (2011) 0.95
Mitral regurgitation following acute myocardial infarction. Coron Artery Dis (2002) 0.94
Myocardial bridging in absence of coronary artery disease: proposal of a new classification based on clinical-angiographic data and long-term follow-up. Cardiology (2008) 0.93
Administration of vascular endothelial growth factor adjunctive to fetal cardiomyocyte transplantation and improvement of cardiac function in the rat model. J Cardiovasc Pharmacol Ther (2005) 0.92
Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol (2007) 0.92
Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: Comprehensive systematic review and meta-analysis of randomized controlled trials. Cardiovasc Revasc Med (2013) 0.90
The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame. J Cardiovasc Pharmacol Ther (2007) 0.90
Monocyte chemoattractant protein 1-induced monocyte infiltration produces angiogenesis but not arteriogenesis in chronically infarcted myocardium. J Cardiovasc Pharmacol Ther (2004) 0.87
Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol (2006) 0.87
Reduction of infarct size by short-term pretreatment with atorvastatin. Cardiovasc Drugs Ther (2003) 0.87
Outcomes after carotid artery stenting and endarterectomy in the Medicare population. Stroke (2011) 0.85
Prasugrel-induced rash. Ann Pharmacother (2012) 0.84
Mediating delta-opioid-initiated heart protection via the beta2-adrenergic receptor: role of the intrinsic cardiac adrenergic cell. Am J Physiol Heart Circ Physiol (2007) 0.83
Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J (2004) 0.83
Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: clinical evidence and possible underlying mechanisms. Am Heart J (2007) 0.83
Reducing ischaemia/reperfusion injury through delta-opioid-regulated intrinsic cardiac adrenergic cells: adrenopeptidergic co-signalling. Cardiovasc Res (2009) 0.82
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. J Cardiovasc Pharmacol Ther (2008) 0.82
Time to reperfusion in acute myocardial infarction. It is time to reduce it! J Electrocardiol (2007) 0.81
Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2. Prostaglandins Other Lipid Mediat (2007) 0.81
Should serum troponin after PCI be used to predict long-term outcomes?.......Not quite yet! Catheter Cardiovasc Interv (2011) 0.81
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol (2007) 0.79
U.S. Trends in Inpatient Utilization of Fractional Flow Reserve and Percutaneous Coronary Intervention. J Am Coll Cardiol (2016) 0.79
Task force 13: training in advanced cardiovascular imaging (computed tomography). J Cardiovasc Comput Tomogr (2008) 0.79
Entrapment of a cerebral embolic protection device--a case report. Vasc Endovascular Surg (2006) 0.79
Noncoronary complications of coronary intervention. Catheter Cardiovasc Interv (2002) 0.79
Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillation, previous left atrial thrombus and effective anticoagulation. Int J Cardiol (2006) 0.79
Benefits, unresolved questions, and technical issues of cardiac resynchronization therapy for heart failure. Am J Cardiol (2005) 0.79
Developments in coronary chronic total occlusion percutaneous coronary interventions: 2014 state-of-the-art update. J Invasive Cardiol (2014) 0.79
Quality assessment and improvement in interventional cardiology: a position statement of the Society of Cardiovascular Angiography and Interventions, part 1: standards for quality assessment and improvement in interventional cardiology. Catheter Cardiovasc Interv (2011) 0.78
Vasopressin antagonism: a future treatment option in heart failure. Eur Heart J (2005) 0.78
Conversations in cardiology: bridging antiplatelet therapy before surgery. Catheter Cardiovasc Interv (2014) 0.78
Manual aspiration thrombectomy in acute ST elevation myocardial infarction: New gold standard. World J Cardiol (2011) 0.77
Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data. J Am Heart Assoc (2013) 0.77
AAV2/8-hSMAD3 gene delivery attenuates aortic atherogenesis, enhances Th2 response without fibrosis, in LDLR-KO mice on high cholesterol diet. J Transl Med (2014) 0.77
Atresia of the left internal mammary artery graft following percutaneous intervention of the left main. J Invasive Cardiol (2011) 0.77
Effect of chronic angiotensin converting enzyme inhibitor therapy on myocardial injury in patients undergoing percutaneous coronary interventions. J Invasive Cardiol (2011) 0.76
Cardiac calcitonin gene-related peptide and left ventricular hypertrophy in the cardiac allograft. J Heart Lung Transplant (2009) 0.76
Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv (2007) 0.76
Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion. Cardiovasc Drugs Ther (2011) 0.76
Gadodiamide-based coronary angiography in a patient with severe renal insufficiency. J Interv Cardiol (2005) 0.76
Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels. Coron Artery Dis (2004) 0.75
Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. Expert Opin Investig Drugs (2006) 0.75
Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med (2008) 0.75
Time for left main stenting in patients with LV dysfunction? Proceed with caution! Catheter Cardiovasc Interv (2010) 0.75
Does mini-STAR equal mega-success? Catheter Cardiovasc Interv (2012) 0.75
Primary PCI for the "late presenter" with STEMI: how late is too late? Catheter Cardiovasc Interv (2010) 0.75
Normal fractional flow reserve with a critical stenosis supplying viable myocardium. Exp Clin Cardiol (2012) 0.75
Infective coronary aneurysms: a complication of percutaneous coronary intervention. Tex Heart Inst J (2007) 0.75
Reply: To PMID 23083781. J Am Coll Cardiol (2013) 0.75
Chronic pseudoaneurysm and coarctation of the aorta: a rare delayed complication of trauma. Tex Heart Inst J (2006) 0.75
Advancing backward: a word of caution. Catheter Cardiovasc Interv (2008) 0.75
The value of recanalizing a chronic total occlusion. Catheter Cardiovasc Interv (2011) 0.75
Optimizing bifurcation stenting: the SPRINT technique. Catheter Cardiovasc Interv (2009) 0.75
IIb or not IIb? Toward a rational application of left main stenting. J Am Coll Cardiol (2010) 0.75
"Drip-and-ship," "Stay-and-pray," "Freight-and-wait (and possibly inflate)" or simply opening the window wider?: Decision-making regarding time delays in the treatment of ST elevation MI. Catheter Cardiovasc Interv (2009) 0.75